Childhood-onset IgA nephropathy: is long-term recovery possible?
Hematuria
MEST-C score
Proteinuria
Relapse
Remission
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
16 Jan 2024
16 Jan 2024
Historique:
received:
25
09
2023
accepted:
13
12
2023
revised:
24
11
2023
medline:
16
1
2024
pubmed:
16
1
2024
entrez:
15
1
2024
Statut:
aheadofprint
Résumé
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide. While studies have primarily focused on identifying risk factors for disease progression, very few data exist on the likelihood of achieving complete recovery from the disease. We conducted a single-center retrospective study on all consecutive patients with biopsy-proven IgAN diagnosed between 1986 and 2018 in our pediatric center. Biopsies were classified according to the MEST-C Oxford classification score. "Complete clinical remission" was defined as the absence of proteinuria, hematuria, and hypertension in patients with normal kidney function who had been off therapy for more than 2 years. Overall, 153 patients with age at onset of 10.6 ± 4 years were enrolled in the study. Of these, 41 achieved "complete clinical remission." The estimated probability of complete clinical remission at 10 years was 43% (95%CI 33-54). However, seven patients relapsed within 10 years. Multivariable analysis showed that higher age at onset (HR 0.89, 95%CI 0.80-0.98, p = 0.017) and segmental glomerulosclerosis lesions (HR 0.28, 95%CI 0.10-0.79, p = 0.017) decreased significantly the chances of achieving complete clinical remission. Immunosuppressive therapy was not significantly associated with clinical outcomes. Approximately one-third of patients with pediatric-onset IgAN achieve prolonged remission, in particular, very young children at disease onset without sclerotic glomerular lesions. Longer term follow-up is needed to assess if these patients have achieved permanent remission.
Sections du résumé
BACKGROUND
BACKGROUND
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide. While studies have primarily focused on identifying risk factors for disease progression, very few data exist on the likelihood of achieving complete recovery from the disease.
METHODS
METHODS
We conducted a single-center retrospective study on all consecutive patients with biopsy-proven IgAN diagnosed between 1986 and 2018 in our pediatric center. Biopsies were classified according to the MEST-C Oxford classification score. "Complete clinical remission" was defined as the absence of proteinuria, hematuria, and hypertension in patients with normal kidney function who had been off therapy for more than 2 years.
RESULTS
RESULTS
Overall, 153 patients with age at onset of 10.6 ± 4 years were enrolled in the study. Of these, 41 achieved "complete clinical remission." The estimated probability of complete clinical remission at 10 years was 43% (95%CI 33-54). However, seven patients relapsed within 10 years. Multivariable analysis showed that higher age at onset (HR 0.89, 95%CI 0.80-0.98, p = 0.017) and segmental glomerulosclerosis lesions (HR 0.28, 95%CI 0.10-0.79, p = 0.017) decreased significantly the chances of achieving complete clinical remission. Immunosuppressive therapy was not significantly associated with clinical outcomes.
CONCLUSIONS
CONCLUSIONS
Approximately one-third of patients with pediatric-onset IgAN achieve prolonged remission, in particular, very young children at disease onset without sclerotic glomerular lesions. Longer term follow-up is needed to assess if these patients have achieved permanent remission.
Identifiants
pubmed: 38225439
doi: 10.1007/s00467-023-06259-4
pii: 10.1007/s00467-023-06259-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Références
D’Amico G (1987) The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 64:709–727
pubmed: 3329736
Wyatt RJ, Julian BA (2013) IgA nephropathy. N Engl J Med 368:2402–2414. https://doi.org/10.1056/NEJMra1206793
doi: 10.1056/NEJMra1206793
pubmed: 23782179
Schena FP, Nistor I (2018) Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol 38:435–442. https://doi.org/10.1016/j.semnephrol.2018.05.013
doi: 10.1016/j.semnephrol.2018.05.013
pubmed: 30177015
Coppo R (2019) Pediatric IgA nephropathy in Europe. Kidney Dis (Basel) 5:182–188. https://doi.org/10.1159/000495751
doi: 10.1159/000495751
pubmed: 31259180
pmcid: 6587208
Reich HN, Troyanov S, Scholey JW, Cattran DC (2007) Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18:3177–3183. https://doi.org/10.1681/asn.2007050526
doi: 10.1681/asn.2007050526
pubmed: 17978307
Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, Steenkamp R, Wong K, Turner AN, Wang K, Gale DP, Barratt J (2023) Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol 18:727–738. https://doi.org/10.2215/cjn.0000000000000135
doi: 10.2215/cjn.0000000000000135
pubmed: 37055195
Coppo R (2017) Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients. J Nephrol 30:339–346. https://doi.org/10.1007/s40620-016-0360-z
doi: 10.1007/s40620-016-0360-z
pubmed: 27815919
Barbour SJ, Coppo R, Er L, Russo ML, Liu ZH, Ding J, Katafuchi R, Yoshikawa N, Xu H, Kagami S, Yuzawa Y, Emma F, Cambier A, Peruzzi L, Wyatt RJ, Cattran DC (2021) Updating the International IgA Nephropathy Prediction Tool for use in children. Kidney Int 99:1439–1450. https://doi.org/10.1016/j.kint.2020.10.033
doi: 10.1016/j.kint.2020.10.033
pubmed: 33220356
Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D’Agati V, D’Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76:534–545. https://doi.org/10.1038/ki.2009.243
doi: 10.1038/ki.2009.243
pubmed: 19571791
Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J (2017) Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int 91:1014–1021. https://doi.org/10.1016/j.kint.2017.02.003
doi: 10.1016/j.kint.2017.02.003
pubmed: 28341274
Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263
doi: 10.1542/peds.58.2.259
pubmed: 951142
Gao A, Cachat F, Faouzi M, Bardy D, Mosig D, Meyrat BJ, Girardin E, Chehade H (2013) Comparison of the glomerular filtration rate in children by the new revised Schwartz formula and a new generalized formula. Kidney Int 83:524–530. https://doi.org/10.1038/ki.2012.388
doi: 10.1038/ki.2012.388
pubmed: 23254901
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
doi: 10.7326/0003-4819-150-9-200905050-00006
pubmed: 19414839
pmcid: 2763564
Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, Invitti C, Litwin M, Mancia G, Pall D, Rascher W, Redon J, Schaefer F, Seeman T, Sinha M, Stabouli S, Webb NJ, Wühl E, Zanchetti A (2016) 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 34:1887–1920. https://doi.org/10.1097/hjh.0000000000001039
doi: 10.1097/hjh.0000000000001039
pubmed: 27467768
Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE, Griffith KE, Hemmelgarn BR, Iseki K, Lamb EJ, Levey AS, Riella MC, Shlipak MG, Wang H, White CT, Winearls CG (2013) Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150
Coppo R, Robert T (2020) IgA nephropathy in children and in adults: two separate entities or the same disease? J Nephrol 33:1219–1229. https://doi.org/10.1007/s40620-020-00725-0
doi: 10.1007/s40620-020-00725-0
pubmed: 32314305
Haas M, Rahman MH, Cohn RA, Fathallah-Shaykh S, Ansari A, Bartosh SM (2008) IgA nephropathy in children and adults: comparison of histologic features and clinical outcomes. Nephrol Dial Transplant 23:2537–2545. https://doi.org/10.1093/ndt/gfn014
doi: 10.1093/ndt/gfn014
pubmed: 18263928
Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, Feehally J, Roberts IS, Amore A, Alpers CE, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D’Agati V, D’Amico G, Emancipator SN, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo AB, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2010) The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 77:921–927. https://doi.org/10.1038/ki.2010.43
doi: 10.1038/ki.2010.43
pubmed: 20200498
Sevillano AM, Gutiérrez E, Yuste C, Cavero T, Mérida E, Rodríguez P, García A, Morales E, Fernández C, Martínez MA, Moreno JA, Praga M (2017) Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol 28:3089–3099. https://doi.org/10.1681/asn.2017010108
doi: 10.1681/asn.2017010108
pubmed: 28592423
pmcid: 5619972
Shima Y, Nakanishi K, Kamei K, Togawa H, Nozu K, Tanaka R, Sasaki S, Iijima K, Yoshikawa N (2011) Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy. Nephrol Dial Transplant 26:163–169. https://doi.org/10.1093/ndt/gfq387
doi: 10.1093/ndt/gfq387
pubmed: 20601366
Suh JS, Jang KM, Hyun H, Cho MH, Lee JH, Park YS, Oh JH, Kim JH, Yoo KH, Chung WY, Kim SH, Kim K, Lee DY, Lee JW, Cho MH, Park H, Koo JW, Han KH, Yang EM, Lee KH, Shin JI, Cho H, Kim KS, Ha IS, Park YH, Kang HG (2020) Remission of proteinuria may protect against progression to chronic kidney disease in pediatric-onset IgA nephropathy. J Clin Med 9. https://doi.org/10.3390/jcm9072058
Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT, Roberts IS, Peruzzi L, Amore A, Emma F, Fuiano L, Berg U, Topaloglu R, Bilginer Y, Gesualdo L, Polci R, Mizerska-Wasiak M, Caliskan Y, Lundberg S, Cancarini G, Geddes C, Wetzels J, Wiecek A, Durlik M, Cusinato S, Rollino C, Maggio M, Praga M, H KS, Tesar V, Maixnerova D, Barratt J, Papalia T, Bonofiglio R, Mazzucco G, Giannakakis C, Soderberg M, Orhan D, Di Palma AM, Maldyk J, Ozluk Y, Sudelin B, Tardanico R, Kipgen D, Steenbergen E, Karkoszka H, Perkowska-Ptasinska A, Ferrario F, Gutierrez E, Honsova E (2017) Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Pediatr Nephrol 32:139–150. https://doi.org/10.1007/s00467-016-3469-3
doi: 10.1007/s00467-016-3469-3
pubmed: 27557557
Suzuki Y, Matsuzaki K, Suzuki H, Sakamoto N, Joh K, Kawamura T, Tomino Y, Matsuo S (2014) Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol 18:481–486. https://doi.org/10.1007/s10157-013-0849-x
doi: 10.1007/s10157-013-0849-x
pubmed: 23913115
Yoshikawa N, Ito H, Nakamura H (1992) Prognostic indicators in childhood IgA nephropathy. Nephron 60:60–67. https://doi.org/10.1159/000186706
doi: 10.1159/000186706
pubmed: 1738416
Koyama A, Igarashi M, Kobayashi M (1997) Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis 29:526–532. https://doi.org/10.1016/s0272-6386(97)90333-4
doi: 10.1016/s0272-6386(97)90333-4
pubmed: 9100040
Matsushita S, Ishikura K, Okamoto S, Okuda Y, Nagaoka Y, Harada R, Hamada R, Sakai T, Hamasaki Y, Hataya H, Ando T, Ogata K, Honda M (2015) Long-term morbidity of IgA nephropathy in children evaluated with newly proposed remission criteria in Japan. Clin Exp Nephrol 19:1149–1156. https://doi.org/10.1007/s10157-015-1105-3
doi: 10.1007/s10157-015-1105-3
pubmed: 25800961
Nozawa R, Suzuki J, Takahashi A, Isome M, Kawasaki Y, Suzuki S, Suzuki H (2005) Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation. Clin Nephrol 64:171–179. https://doi.org/10.5414/cnp64171
doi: 10.5414/cnp64171
pubmed: 16175941
Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Sako M, Kaito H, Nozu K, Tanaka R, Iijima K, Yoshikawa N (2013) Spontaneous remission in children with IgA nephropathy. Pediatr Nephrol 28:71–76. https://doi.org/10.1007/s00467-012-2294-6
doi: 10.1007/s00467-012-2294-6
pubmed: 22940909
Higa A, Shima Y, Hama T, Sato M, Mukaiyama H, Togawa H, Tanaka R, Nozu K, Sako M, Iijima K, Nakanishi K, Yoshikawa N (2015) Long-term outcome of childhood IgA nephropathy with minimal proteinuria. Pediatr Nephrol 30:2121–2127. https://doi.org/10.1007/s00467-015-3176-5
doi: 10.1007/s00467-015-3176-5
pubmed: 26238276
Komatsu H, Fujimoto S, Yoshikawa N, Kitamura H, Sugiyama H, Yokoyama H (2016) Clinical manifestations of Henoch-Schönlein purpura nephritis and IgA nephropathy: comparative analysis of data from the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol 20:552–560. https://doi.org/10.1007/s10157-015-1177-0
doi: 10.1007/s10157-015-1177-0
pubmed: 26456327
Coppo R, D’Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, Cattran D, Cook TH, Feehally J, Tesar V, Maixnerova D, Peruzzi L, Amore A, Lundberg S, Di Palma AM, Gesualdo L, Emma F, Rollino C, Praga M, Biancone L, Pani A, Feriozzi S, Polci R, Barratt J, Del Vecchio L, Locatelli F, Pierucci A, Caliskan Y, Perkowska-Ptasinska A, Durlik M, Moggia E, Ballarin JC, Wetzels JFM, Goumenos D, Papasotiriou M, Galesic K, Toric L, Papagianni A, Stangou M, Benozzi L, Cusinato S, Berg U, Topaloglu R, Maggio M, Ots-Rosenberg M, D’Amico M, Geddes C, Balafa O, Quaglia M, Cravero R, Lino Cirami C, Fellstrom B, Floege J, Egido J, Mallamaci F, Zoccali C (2020) Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrol Dial Transplant 35:1002–1009. https://doi.org/10.1093/ndt/gfy302
doi: 10.1093/ndt/gfy302
pubmed: 30418652
Wu H, Xia Z, Gao C, Zhang P, Yang X, Wang R, Wang M, Peng Y (2020) The correlation analysis between the Oxford classification of Chinese IgA nephropathy children and renal outcome - a retrospective cohort study. BMC Nephrol 21:247. https://doi.org/10.1186/s12882-020-01913-7
doi: 10.1186/s12882-020-01913-7
pubmed: 32611399
pmcid: 7329550